Children's oncology Group's 2013 blueprint for research

Acute lymphoblastic leukemia

Stephen P. Hunger, Mignon L. Loh, James A. Whitlock, Naomi J. Winick, William L. Carroll, Meenakshi Devidas, Elizabeth A. Raetz

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

Original languageEnglish (US)
Pages (from-to)957-963
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Research
Drug Therapy
Survival
Young Adult
T-Lymphocytes
Mutation
Therapeutics

Keywords

  • Acute lymphoblastic leukemia (ALL)
  • COG ALL trials

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Hunger, S. P., Loh, M. L., Whitlock, J. A., Winick, N. J., Carroll, W. L., Devidas, M., & Raetz, E. A. (2013). Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia. Pediatric Blood and Cancer, 60(6), 957-963. https://doi.org/10.1002/pbc.24420

Children's oncology Group's 2013 blueprint for research : Acute lymphoblastic leukemia. / Hunger, Stephen P.; Loh, Mignon L.; Whitlock, James A.; Winick, Naomi J.; Carroll, William L.; Devidas, Meenakshi; Raetz, Elizabeth A.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 06.2013, p. 957-963.

Research output: Contribution to journalArticle

Hunger, SP, Loh, ML, Whitlock, JA, Winick, NJ, Carroll, WL, Devidas, M & Raetz, EA 2013, 'Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia', Pediatric Blood and Cancer, vol. 60, no. 6, pp. 957-963. https://doi.org/10.1002/pbc.24420
Hunger, Stephen P. ; Loh, Mignon L. ; Whitlock, James A. ; Winick, Naomi J. ; Carroll, William L. ; Devidas, Meenakshi ; Raetz, Elizabeth A. / Children's oncology Group's 2013 blueprint for research : Acute lymphoblastic leukemia. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 957-963.
@article{d69b91554d834e3fa20db028322d5d4e,
title = "Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia",
abstract = "Approximately 90{\%} of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.",
keywords = "Acute lymphoblastic leukemia (ALL), COG ALL trials",
author = "Hunger, {Stephen P.} and Loh, {Mignon L.} and Whitlock, {James A.} and Winick, {Naomi J.} and Carroll, {William L.} and Meenakshi Devidas and Raetz, {Elizabeth A.}",
year = "2013",
month = "6",
doi = "10.1002/pbc.24420",
language = "English (US)",
volume = "60",
pages = "957--963",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Children's oncology Group's 2013 blueprint for research

T2 - Acute lymphoblastic leukemia

AU - Hunger, Stephen P.

AU - Loh, Mignon L.

AU - Whitlock, James A.

AU - Winick, Naomi J.

AU - Carroll, William L.

AU - Devidas, Meenakshi

AU - Raetz, Elizabeth A.

PY - 2013/6

Y1 - 2013/6

N2 - Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

AB - Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

KW - Acute lymphoblastic leukemia (ALL)

KW - COG ALL trials

UR - http://www.scopus.com/inward/record.url?scp=84876442551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876442551&partnerID=8YFLogxK

U2 - 10.1002/pbc.24420

DO - 10.1002/pbc.24420

M3 - Article

VL - 60

SP - 957

EP - 963

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -